Short-term single blood thinner after LAmbre device implant
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether it is safe and effective to use just one blood thinner (aspirin or clopidogrel) for a short time after getting a LAmbre device implanted to close off a heart pouch that can cause strokes. It is for people with atrial fibrillation who cannot take standard blood thinners long-term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have atrial fibrillation (irregular heartbeat) not caused by a mechanical heart valve or severe mitral valve disease.
- Your stroke risk score (CHA2DS2-VASc) is high: 2 or more for men, 3 or more for women.
- You cannot take blood thinners long-term.
- You have already received a LAmbre device to close the left atrial appendage, and the procedure went smoothly with no problems while you were in the hospital.
- You are willing to come back for follow-up appointments and have signed a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new device (LAmbre Plus) that closes off a small pouch in the heart (left atrial appendage) to reduce stroke risk in people with AFib who cannot take blood thinners long-term. The procedure is an alternative to daily medication.
This trial tests whether patients who receive a special device to close a hole in the heart (to prevent stroke from irregular heartbeat) can safely take fewer blood-thinning medications afterward. The study compares taking a standard blood thinner for 3 months versus taking aspirin only, to see which approach works best with fewer bleeding risks.
This trial compares which two medicines work best after a device closes off a part of the heart called the left atrial appendage. It may help reduce stroke risk while balancing bleeding risk after your procedure.
This trial studies a “double anti-platelet” medicine plan (aspirin plus clopidogrel) after closing the left atrial appendage, a procedure used to reduce stroke risk in some heart rhythm conditions. It aims to find a safer, better medicine strategy for people who cannot take standard blood thinners.
This trial compares a heart device that can help prevent blood clots in the heart (called LAAO) versus long-term blood thinners for people who have atrial fibrillation and recently had a stent placed. It aims to see which approach better prevents stroke and related blood-clot problems while keeping side effects manageable.
This study looks at whether a lower-dose blood thinner works as well as the usual recommended anti-clot treatment after a procedure that closes off the heart’s left atrial appendage. It may help reduce bleeding risk while still preventing dangerous blood clots.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.